MX340458B - Método para elaborar micropartículas de liberación sostenida. - Google Patents

Método para elaborar micropartículas de liberación sostenida.

Info

Publication number
MX340458B
MX340458B MX2011005904A MX2011005904A MX340458B MX 340458 B MX340458 B MX 340458B MX 2011005904 A MX2011005904 A MX 2011005904A MX 2011005904 A MX2011005904 A MX 2011005904A MX 340458 B MX340458 B MX 340458B
Authority
MX
Mexico
Prior art keywords
sustained release
release microparticles
active agent
making sustained
various embodiments
Prior art date
Application number
MX2011005904A
Other languages
English (en)
Other versions
MX2011005904A (es
Inventor
Chithambara Thanoo Bagavathikanun
Iii Johns Gonto
Ho Woo Byung
Original Assignee
Oakwood Laboratories LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42231354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX340458(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oakwood Laboratories LLC filed Critical Oakwood Laboratories LLC
Publication of MX2011005904A publication Critical patent/MX2011005904A/es
Publication of MX340458B publication Critical patent/MX340458B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen diversas modalidades de un método para preparar micropartículas de liberación sostenida. En una modalidad, el método incluye las etapas de formar una fase dispersa de un agente activo en un polímero y combinar la fase dispersa con una fase continua para formar una dispersión de micropartículas. El método además incluye la etapa de agregar una cantidad medida de una composición de dilución a la dispersión de micropartículas. Se ha encontrado en este documento que las diversas modalidades para preparar micropartículas de liberación sostenida, al utilizar diversas cantidades de la composición de dilución, altera la tasa de liberación de la micropartícula de liberación sostenida para el agente activo específico.
MX2011005904A 2008-12-04 2009-12-01 Método para elaborar micropartículas de liberación sostenida. MX340458B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/328,136 US20100143479A1 (en) 2008-12-04 2008-12-04 Method of making sustained release microparticles
PCT/US2009/066212 WO2010065513A1 (en) 2008-12-04 2009-12-01 Method of making sustained release microparticles

Publications (2)

Publication Number Publication Date
MX2011005904A MX2011005904A (es) 2011-09-27
MX340458B true MX340458B (es) 2016-07-08

Family

ID=42231354

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011005904A MX340458B (es) 2008-12-04 2009-12-01 Método para elaborar micropartículas de liberación sostenida.

Country Status (9)

Country Link
US (2) US20100143479A1 (es)
EP (1) EP2379055B1 (es)
JP (1) JP6172887B2 (es)
CN (1) CN102271660B (es)
BR (1) BRPI0922821A2 (es)
CA (2) CA2745784A1 (es)
ES (1) ES2655890T3 (es)
MX (1) MX340458B (es)
WO (1) WO2010065513A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2471303A (en) 2009-06-24 2010-12-29 Bell Flavors & Fragrances Duft Und Aroma Gmbh Microparticles and method of making microparticles
CN103191021A (zh) * 2012-01-10 2013-07-10 山东绿叶制药有限公司 一种连续生产微球的设备及其应用
JP6135292B2 (ja) * 2013-05-10 2017-05-31 ニプロ株式会社 マイクロカプセル製剤の製造方法
JP2016102093A (ja) * 2014-11-28 2016-06-02 ニプロ株式会社 塩基性の求核化合物を含有するマイクロカプセルの製造方法
BR112018009644A2 (pt) 2015-11-12 2018-11-06 Graybug Vision Inc micropartículas agregantes sólidas modificadas na superfície, material injetável, processo para preparação de micropartículas agregantes sólidas modificadas na superfície, método para tratamento de um distúrbio ocular, e, uso de micropartículas agregantes sólidas modificadas na superfície
US20190380967A1 (en) * 2017-01-23 2019-12-19 Savior Lifetec Corporation Preparation of microparticles of an active ingredient
WO2018175922A1 (en) 2017-03-23 2018-09-27 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
CN111201040A (zh) 2017-05-10 2020-05-26 灰色视觉公司 用于医学疗法的缓释微粒及其悬浮液
KR20210029210A (ko) 2018-06-29 2021-03-15 악스톤 바이오사이언시스 코퍼레이션 초장기 작용 인슐린-fc 융합 단백질 및 사용 방법
EP4125823A1 (en) 2020-03-30 2023-02-08 Biological E Limited Risperidone microspheres, process for their prepartion and uses thereof
CA3267932A1 (en) 2022-10-05 2024-04-11 Mireca Medicines Gmbh MICROPARCEL AND IMPLANT FORMULATIONS FOR ANALOGUE CGMP THERAPY

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US6270802B1 (en) * 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
US6495166B1 (en) 1999-11-12 2002-12-17 Alkermes Controlled Therapeutics Inc. Apparatus and method for preparing microparticles using in-line solvent extraction
US6705757B2 (en) * 1999-11-12 2004-03-16 Alkermes Controlled Therapeutics, Inc. Ii Method and apparatus for preparing microparticles using in-line solvent extraction
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
CA2915574C (en) * 2003-07-18 2017-02-07 Oakwood Laboratories, L.L.C. Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions

Also Published As

Publication number Publication date
EP2379055A1 (en) 2011-10-26
CA2745784A1 (en) 2010-06-10
EP2379055A4 (en) 2012-06-13
ES2655890T3 (es) 2018-02-22
MX2011005904A (es) 2011-09-27
WO2010065513A1 (en) 2010-06-10
JP6172887B2 (ja) 2017-08-02
JP2012511003A (ja) 2012-05-17
CA2765695A1 (en) 2010-06-10
BRPI0922821A2 (pt) 2015-12-22
CA2765695C (en) 2018-01-02
US20180177785A1 (en) 2018-06-28
EP2379055B1 (en) 2017-11-08
US20100143479A1 (en) 2010-06-10
CN102271660B (zh) 2018-04-06
CN102271660A (zh) 2011-12-07

Similar Documents

Publication Publication Date Title
MX340458B (es) Método para elaborar micropartículas de liberación sostenida.
MX342439B (es) Metodos para producir nanoparticulas polimericas y formulaciones de ingredientes activos.
SA112330855B1 (ar) تركيبة صيدلانية سريعة الذوبان
IL246074B (en) Peer-to-peer content production network, method and manager
IN2012DN00570A (es)
MX2013005621A (es) Composicion para administracion de farmaco biodegradable.
WO2011159769A3 (en) Indane estrogen receptor modulators and uses thereof
WO2009097508A3 (en) Methods and compositions for wound healing
PH12012502419A1 (en) Estrogen receptor modulators and uses thereof
MX2013002975A (es) Moduladores de receptores de estrogenos y usos de los mismos.
CL2008003092A1 (es) Producto de dispersion solida que comprende a una agente activo derivado de n-aril urea, un agente formador de matriz seleccionado entre ciclodextrinas, polimeros, lipidos y un tensioactivo no ionico; proceso de preparacion de dicho producto de dispersion; y forma dosificacion farmaceutica que lo comprende .
WO2010017215A3 (en) Biodegradable microspheres and methods of use thereof
MY172545A (en) Cement compositions comprising deagglomerated inorganic nanotubes and associated methods
MY150660A (en) Dividable galenical form allowing modified release of the active ingredient
PL2767531T3 (pl) Cykliczne N,N'-diarylotiomoczniki i N,N'-diarylomoczniki jako antagoniści receptora androgenu, lek przeciwnowotworowy, sposób ich wytwarzania i stosowania
WO2013079605A3 (en) Polymeric drug-delivery material, method for manufacturing thereof and method for delivery of a drug-delivery composition
UA114534C2 (uk) Бітумна композиція у формі гранул та спосіб її одержання
WO2012073170A3 (fr) Composition galénique adaptée à l'administration à un animal non-humain, utilisations de celle-ci et méthodes associées
FR2936950B1 (fr) Composition cosmetique comprenant un copolymere amphiphile zwitterionique
FR2969653B1 (fr) Dispersion organique de particules a base de fer sous forme cristallisee
BRPI0920683A2 (pt) Composto, composição de composto ativo, semente, medicamento, e, métodos para controlar fungos fitopatogênicos, e para preparar um agente antimicótico
MX339755B (es) Polvo de polisacarido y poliol compresible y altamente viscoso.
WO2014060443A3 (en) A composite scaffold for use as a tissue engineering implant
WO2010079052A3 (en) Nanoparticle compositions
WO2012003495A3 (en) Automated equipment for hydration, mixing and delivery of alginate to a pellet forming device

Legal Events

Date Code Title Description
FG Grant or registration